|
Association between post-treatment (tx) alpha-fetoprotein (AFP) reduction and outcomes in real-world (rw) U.S. patients (pts) with advanced HCC (aHCC). |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Roche |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health |
|
|
No Relationships to Disclose |
|
|
Employment - Flatiron Health |
Stock and Other Ownership Interests - Flatiron Health; Roche |
Consulting or Advisory Role - Grand Rounds (I) |
Other Relationship - De Luca Foundation |
|
|
Honoraria - Bristol-Myers Squibb; Lilly |
Consulting or Advisory Role - Array BioPharma; Bayer; Bristol-Myers Squibb; Lilly |
|
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst) |
|
|
Consulting or Advisory Role - Agios; AstraZeneca; Autem Medical; Bayer; BeiGene; Berry Genomics; Celgene; CytomX Therapeutics (I); Eisai; Flatiron Health; Genoscience Pharma; Gilead Sciences; Gilead Sciences; Incyte; Ipsen; LAM Therapeutics; Lilly; Loxo (I); Merck Serono; Minapharma; QED Therapeutics; RedHill Biopharma; Roche/Genentech; Silenseed (I); Sillajen; SOBI (I); TheraBionic; twoXAR; Vector Health; Yiviva |
Research Funding - Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); CASI Pharmaceuticals (Inst); Exelixis (Inst); Incyte (Inst); Polaris (Inst); Puma Biotechnology (Inst); QED Therapeutics (Inst) |
Travel, Accommodations, Expenses - Polaris |